{
    "clinical_study": {
        "@rank": "137698", 
        "arm_group": {
            "arm_group_label": "Topiramate"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the long-term retention rate of topiramate in\n      participants with epilepsy (seizure disorder)."
        }, 
        "brief_title": "An Observational Study to Evaluate Long-term Retention Rate of Topiramate in Participants With Epilepsy", 
        "clinical_results": {
            "baseline": {
                "group_list": {
                    "group": {
                        "@group_id": "B1", 
                        "description": "This was an observational study. Participants with seizures received topiramate as per Investigator\u2019s discretion were observed.", 
                        "title": "Topiramate"
                    }
                }, 
                "measure_list": {
                    "measure": [
                        {
                            "category_list": {
                                "category": {
                                    "measurement_list": {
                                        "measurement": {
                                            "@group_id": "B1", 
                                            "@value": "1232"
                                        }
                                    }
                                }
                            }, 
                            "param": "Number", 
                            "title": "Number of Participants", 
                            "units": "participants"
                        }, 
                        {
                            "category_list": {
                                "category": {
                                    "measurement_list": {
                                        "measurement": {
                                            "@group_id": "B1", 
                                            "@spread": "17.10", 
                                            "@value": "24.07"
                                        }
                                    }
                                }
                            }, 
                            "dispersion": "Standard Deviation", 
                            "param": "Mean", 
                            "title": "Age", 
                            "units": "Years"
                        }, 
                        {
                            "category_list": {
                                "category": [
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "562"
                                            }
                                        }, 
                                        "sub_title": "Female"
                                    }, 
                                    {
                                        "measurement_list": {
                                            "measurement": {
                                                "@group_id": "B1", 
                                                "@value": "670"
                                            }
                                        }, 
                                        "sub_title": "Male"
                                    }
                                ]
                            }, 
                            "param": "Number", 
                            "title": "Gender", 
                            "units": "Participants"
                        }
                    ]
                }, 
                "population": "Full analysis set (FAS) population included all participants who met all the eligibility criteria."
            }, 
            "certain_agreements": {
                "pi_employee": "Principal Investigators are NOT employed by the organization sponsoring the study.", 
                "restrictive_agreement": "PI cannot provide any trial related information to external parties\u2019 without mutual agreement with the Sponsor. This is valid even after the contract is canceled."
            }, 
            "limitations_and_caveats": "The study design is single arm and open label, so bias could not be excluded in the subjective evaluation by Participants and Investigators.", 
            "outcome_list": {
                "outcome": [
                    {
                        "description": "Participants with long term retention of topiramate until 52 weeks were reported", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "This was an observational study. Participants with seizures received topiramate as per Investigator\u2019s discretion were observed.", 
                                "title": "Topiramate"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "1232"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@lower_limit": "68.95", 
                                                    "@upper_limit": "73.99", 
                                                    "@value": "71.56"
                                                }
                                            }
                                        }
                                    }, 
                                    "description": "Participants with long term retention of topiramate until 52 weeks were reported", 
                                    "dispersion": "95% Confidence Interval", 
                                    "param": "Number", 
                                    "title": "Percentage of Participants Retained to Topiramate Treatment", 
                                    "units": "Percentage of participants"
                                }
                            ]
                        }, 
                        "population": "The full analysis set (FAS) population included all participants who met all the eligibility criteria.", 
                        "safety_issue": "No", 
                        "time_frame": "Week 52", 
                        "title": "Percentage of Participants Retained to Topiramate Treatment", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "Number of participants who received concomitant AEDs along with the topiramate were reported.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "This was an observational study. Participants with seizures received topiramate as per Investigator\u2019s discretion were observed.", 
                                "title": "Topiramate"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "1232"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "749"
                                                }
                                            }
                                        }
                                    }, 
                                    "description": "Number of participants who received concomitant AEDs along with the topiramate were reported.", 
                                    "param": "Number", 
                                    "title": "Number of Participants Who Received Concomitant Antiepileptic Drugs (AEDs)", 
                                    "units": "Participants"
                                }
                            ]
                        }, 
                        "population": "FAS population included all participants who met all the eligibility criteria.", 
                        "safety_issue": "No", 
                        "time_frame": "Baseline up to Week 52", 
                        "title": "Number of Participants Who Received Concomitant Antiepileptic Drugs (AEDs)", 
                        "type": "Secondary"
                    }, 
                    {
                        "description": "Number of participants who received topiramate as first mono-therapy (initial treatment of epilepsy with a single drug), second mono-therapy (second line treatment with a single drug) or add-on therapy (as a supplement therapy to another drug) were reported.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "This was an observational study. Participants with seizures received topiramate as per Investigator\u2019s discretion were observed.", 
                                "title": "Topiramate"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "1232"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": [
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@spread": "0", 
                                                        "@value": "507"
                                                    }
                                                }, 
                                                "sub_title": "First Mono-therapy"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "64"
                                                    }
                                                }, 
                                                "sub_title": "Second Mono-therapy"
                                            }, 
                                            {
                                                "measurement_list": {
                                                    "measurement": {
                                                        "@group_id": "O1", 
                                                        "@value": "661"
                                                    }
                                                }, 
                                                "sub_title": "Add-on therapy"
                                            }
                                        ]
                                    }, 
                                    "description": "Number of participants who received topiramate as first mono-therapy (initial treatment of epilepsy with a single drug), second mono-therapy (second line treatment with a single drug) or add-on therapy (as a supplement therapy to another drug) were reported.", 
                                    "param": "Number", 
                                    "title": "Number of Participants Who Received Topiramate as First Mono-therapy, Second Mono-therapy or Add-on Therapy", 
                                    "units": "Participants"
                                }
                            ]
                        }, 
                        "population": "FAS population included all participants who met all the eligibility criteria.", 
                        "safety_issue": "No", 
                        "time_frame": "Baseline up to Week 52", 
                        "title": "Number of Participants Who Received Topiramate as First Mono-therapy, Second Mono-therapy or Add-on Therapy", 
                        "type": "Secondary"
                    }, 
                    {
                        "description": "Participants without seizure was calculated as percentage of participants who were found to be free of seizures and were observed up to Week 52.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "This was an observational study. Participants with seizures received topiramate as per Investigator\u2019s discretion were observed.", 
                                "title": "Topiramate"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "1232"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@lower_limit": "37.76", 
                                                    "@upper_limit": "43.24", 
                                                    "@value": "40.50"
                                                }
                                            }
                                        }
                                    }, 
                                    "description": "Participants without seizure was calculated as percentage of participants who were found to be free of seizures and were observed up to Week 52.", 
                                    "dispersion": "95% Confidence Interval", 
                                    "param": "Number", 
                                    "title": "Percentage of Participants Without Seizure", 
                                    "units": "Percentage of participants"
                                }
                            ]
                        }, 
                        "population": "FAS population included all participants who met all the eligibility criteria.", 
                        "safety_issue": "No", 
                        "time_frame": "Baseline up to Week 52", 
                        "title": "Percentage of Participants Without Seizure", 
                        "type": "Secondary"
                    }, 
                    {
                        "description": "Percentage of participants for whom seizure frequency was reduced by greater than or equal to 50 percent after topiramate treatment were reported.", 
                        "group_list": {
                            "group": {
                                "@group_id": "O1", 
                                "description": "This was an observational study. Participants with seizures received topiramate as per Investigator\u2019s discretion were observed.", 
                                "title": "Topiramate"
                            }
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@value": "1232"
                                                }
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": {
                                                    "@group_id": "O1", 
                                                    "@lower_limit": "82.10", 
                                                    "@upper_limit": "86.30", 
                                                    "@value": "84.20"
                                                }
                                            }
                                        }
                                    }, 
                                    "description": "Percentage of participants for whom seizure frequency was reduced by greater than or equal to 50 percent after topiramate treatment were reported.", 
                                    "dispersion": "95% Confidence Interval", 
                                    "param": "Number", 
                                    "title": "Percentage of Participants With Reduction in Seizure Frequency by 50 Percent or More", 
                                    "units": "Percentage of participants"
                                }
                            ]
                        }, 
                        "population": "FAS population included all participants who met all the eligibility criteria.", 
                        "safety_issue": "No", 
                        "time_frame": "Week 52", 
                        "title": "Percentage of Participants With Reduction in Seizure Frequency by 50 Percent or More", 
                        "type": "Secondary"
                    }
                ]
            }, 
            "participant_flow": {
                "group_list": {
                    "group": {
                        "@group_id": "P1", 
                        "description": "This was an observational study. Participants with seizures received topiramate as per Investigator\u2019s discretion were observed.", 
                        "title": "Topiramate"
                    }
                }, 
                "period_list": {
                    "period": {
                        "drop_withdraw_reason_list": {
                            "drop_withdraw_reason": [
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "62", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "Lack of Efficacy"
                                }, 
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "1", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "Withdrawal by Subject"
                                }, 
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "10", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "Moved to other hospital"
                                }, 
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "174", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "Lost to Follow-up"
                                }, 
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "46", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "Adverse Event"
                                }, 
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "5", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "tapering of topiramate"
                                }, 
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "21", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "unspecified"
                                }, 
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "13", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "Low compliance"
                                }
                            ]
                        }, 
                        "milestone_list": {
                            "milestone": [
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "1234", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "STARTED"
                                }, 
                                {
                                    "participants_list": {
                                        "participants": {
                                            "#text": "2 Participants were not compliant with eligibility criteria", 
                                            "@count": "1232", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "Treated"
                                }, 
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "902", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "COMPLETED"
                                }, 
                                {
                                    "participants_list": {
                                        "participants": {
                                            "@count": "332", 
                                            "@group_id": "P1"
                                        }
                                    }, 
                                    "title": "NOT COMPLETED"
                                }
                            ]
                        }, 
                        "title": "Overall Study"
                    }
                }
            }, 
            "point_of_contact": {
                "name_or_title": "Clinical Research Associate, Medical affairs", 
                "organization": "Janssen Korea, Location: 25F, LS , Yongsan Tower, 191, Hankangro 2-Ga, Yongsan-Gu, Seoul 140-702, Korea", 
                "phone": "82-2-2094-4837"
            }, 
            "reported_events": {
                "group_list": {
                    "group": {
                        "@group_id": "E1", 
                        "description": "This was an observational study. Participants with seizures received topiramate as per Investigator\u2019s discretion were observed.", 
                        "title": "Topiramate"
                    }
                }, 
                "other_events": {
                    "category_list": {
                        "category": [
                            {
                                "event_list": {
                                    "event": {
                                        "counts": {
                                            "@group_id": "E1", 
                                            "@subjects_affected": "34", 
                                            "@subjects_at_risk": "1234"
                                        }, 
                                        "sub_title": "Total, other adverse events"
                                    }
                                }, 
                                "title": "Total"
                            }, 
                            {
                                "event_list": {
                                    "event": [
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "19", 
                                                "@subjects_at_risk": "1234"
                                            }, 
                                            "sub_title": "Paraesthesia"
                                        }, 
                                        {
                                            "counts": {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "16", 
                                                "@subjects_at_risk": "1234"
                                            }, 
                                            "sub_title": "Weight decreased"
                                        }
                                    ]
                                }, 
                                "title": "Nervous system disorders"
                            }
                        ]
                    }, 
                    "default_assessment": "Non-systematic Assessment", 
                    "default_vocab": "MedDRA Version 15.1", 
                    "frequency_threshold": "1"
                }, 
                "serious_events": {
                    "category_list": {
                        "category": [
                            {
                                "event_list": {
                                    "event": {
                                        "counts": {
                                            "@group_id": "E1", 
                                            "@subjects_affected": "8", 
                                            "@subjects_at_risk": "1234"
                                        }, 
                                        "sub_title": "Total, serious adverse events"
                                    }
                                }, 
                                "title": "Total"
                            }, 
                            {
                                "event_list": {
                                    "event": {
                                        "counts": {
                                            "@group_id": "E1", 
                                            "@subjects_affected": "1", 
                                            "@subjects_at_risk": "1234"
                                        }, 
                                        "sub_title": "Duodenal ulcer perforation"
                                    }
                                }, 
                                "title": "Gastrointestinal disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": {
                                        "counts": {
                                            "@group_id": "E1", 
                                            "@subjects_affected": "5", 
                                            "@subjects_at_risk": "1234"
                                        }, 
                                        "sub_title": "Death"
                                    }
                                }, 
                                "title": "General disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": {
                                        "counts": {
                                            "@group_id": "E1", 
                                            "@subjects_affected": "1", 
                                            "@subjects_at_risk": "1234"
                                        }, 
                                        "sub_title": "Decreased appetite"
                                    }
                                }, 
                                "title": "Metabolism and nutrition disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": {
                                        "counts": {
                                            "@group_id": "E1", 
                                            "@subjects_affected": "1", 
                                            "@subjects_at_risk": "1234"
                                        }, 
                                        "sub_title": "Hepatic neoplasm malignant"
                                    }
                                }, 
                                "title": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)"
                            }
                        ]
                    }, 
                    "default_assessment": "Non-systematic Assessment", 
                    "default_vocab": "MedDRA Version 15.1"
                }, 
                "time_frame": "Baseline up to Week 52"
            }
        }, 
        "completion_date": {
            "#text": "May 2009", 
            "@type": "Actual"
        }, 
        "condition": "Epilepsy", 
        "condition_browse": {
            "mesh_term": "Epilepsy"
        }, 
        "detailed_description": {
            "textblock": "This is an open-label (a medical research study in which participants and researchers are\n      told which treatments the participants are receiving, \"unblinded\"), single-arm, prospective\n      (study following participants forward in time), observational (a clinical study in which\n      participants identified as belonging to study groups are assessed for biomedical or health\n      outcomes) and multi-center (when more than one hospital or medical school team work on a\n      medical research study) study of topiramte in participants with epilesy. The study\n      population will be all the epilepsy participants visiting outpatient study center over a\n      period of two months. Topiramate will be administered as per Investigator's discretion for\n      52 weeks. Participants will visit the trial site for evaluation of endpoint at Baseline,\n      Week 12, Week 26, and Week 52. Efficacy will primarily be evaluated by percentage of\n      participants which will be retained to topiramate treatment uptil Week 52. Participants'\n      safety will be monitored throughout the study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Participants with all type of epilepsy\n\n          -  Participants with more than 2 episodes of seizure during last 1 year\n\n          -  Participants who can comply with the visit schedule and are willing and able to\n             complete evaluation procedures specified in the protocol during the treatment period\n\n          -  Female participants with child bearing potential and who use proper contraceptive\n             methods during the study period\n\n        Exclusion Criteria:\n\n          -  Participants who have known hypersensitivity reaction or allergy to the study drug\n\n          -  Participants who have taken topiramate within the three months of study start\n\n          -  Participants  who are determined not to be suitable for the clinical study\n             participation by an Investigator's discretion\n\n          -  Pregnant and nursing female participants"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "2 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "The study population will include participants with epilepsy who visit an out-patient\n        clinic for two months and have not received topiramate treatment for at least three months\n        prior to Screening."
            }
        }, 
        "enrollment": {
            "#text": "1234", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 22, 2012", 
        "firstreceived_results_date": "June 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01682681", 
            "org_study_id": "CR015865", 
            "secondary_id": "TOPMATEPY4053"
        }, 
        "intervention": {
            "arm_group_label": "Topiramate", 
            "description": "This is an observational study. Participants with seizures receiving topiramate as per Investigator's discretion will be observed.", 
            "intervention_name": "Topiramate", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Topiramate"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Epilepsy", 
            "Topiramate", 
            "Topmax"
        ], 
        "lastchanged_date": "August 21, 2013", 
        "number_of_groups": "1", 
        "official_title": "A Prospective, Observational, Multi-center Study to Assess Long-term Retention Rate of Topiramate in Patients With Epilepsy", 
        "overall_official": {
            "affiliation": "Janssen Korea, Ltd., Korea", 
            "last_name": "Janssen Korea, Ltd., Korea Clinical Trial", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Korea: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "May 2009", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Participants with long term retention of topiramate until 52 weeks were reported", 
            "measure": "Percentage of Participants Retained to Topiramate Treatment", 
            "safety_issue": "No", 
            "time_frame": "Week 52"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01682681"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Number of participants who received concomitant AEDs along with the topiramate were reported.", 
                "measure": "Number of Participants Who Received Concomitant Antiepileptic Drugs (AEDs)", 
                "safety_issue": "No", 
                "time_frame": "Baseline up to Week 52"
            }, 
            {
                "description": "Number of participants who received topiramate as first mono-therapy (initial treatment of epilepsy with a single drug), second mono-therapy (second line treatment with a single drug) or add-on therapy (as a supplement therapy to another drug) were reported.", 
                "measure": "Number of Participants Who Received Topiramate as First Mono-therapy, Second Mono-therapy or Add-on Therapy", 
                "safety_issue": "No", 
                "time_frame": "Baseline up to Week 52"
            }, 
            {
                "description": "Participants without seizure was calculated as percentage of participants who were found to be free of seizures and were observed up to Week 52.", 
                "measure": "Percentage of Participants Without Seizure", 
                "safety_issue": "No", 
                "time_frame": "Baseline up to Week 52"
            }, 
            {
                "description": "Percentage of participants for whom seizure frequency was reduced by greater than or equal to 50 percent after topiramate treatment were reported.", 
                "measure": "Percentage of Participants With Reduction in Seizure Frequency by 50 Percent or More", 
                "safety_issue": "No", 
                "time_frame": "Week 52"
            }
        ], 
        "source": "Janssen Korea, Ltd., Korea", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Janssen Korea, Ltd., Korea", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2007", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "August 2013"
    }
}